Biogen Idec Inc (BIIB) 409.50 $BIIB
Big Week for Biogen
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 4:48PM CDT
Biogen 's investors are in store for a double dose of news this week. On Wednesday, the biotech is scheduled to present data for its Alzheimer's disease drug, aducanumab, and then on Friday we'll get second-quarter earnings from Biogen. Which will...
BIIB: 409.50 (+0.57)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 409.50 (+0.57), RCPT: 228.98 (+0.26), ARNA: 4.30 (-0.05), NVS: 103.71 (-2.41), CELG: 136.24 (+1.01)
Will AmerisourceBergen (ABC) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 11:50AM CDT
AmerisourceBergen carries a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00% and is scheduled to report third-quarter fiscal 2015 results on Jul 23, 2015.
BIIB: 409.50 (+0.57), ABC: 114.10 (-0.66), WBA: 95.66 (+0.01), MDCO: 33.85 (+0.13)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 409.50 (+0.57), SPY: 211.75 (-0.84), GILD: 117.78 (-0.42), ZGNX: 20.72 (+0.34), UTHR: 175.17 (-2.34), RTRX: 34.47 (-0.68), LLY: 85.57 (-2.30), CELG: 136.24 (+1.01), XOMA: 4.39 (-0.13)
Global Inflammatory Bowel Disease Market 2015-2019 - Dominance of Market by Biologics
M2 - Tue Jul 21, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhn6mx/global) has announced the addition of the "Global Inflammatory Bowel Disease Market 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis. The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period. This leads to a rise in the number of treatment-seeking patients, which increases the overall consumption of medicines. According to the report, the high prevalence of inflammatory bowel disease among the population resulting in a rise in the number of treatment-seeking patients has led to increased consumption of medications, thereby having a positive impact on the market share of the vendors. Further, the report states the high cost of drugs used to treat patients suffering from inflammatory bowel disease is one of the major challenges hindering the growth of the market. On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments. - 5-ASA - Antibiotics - Immunomodulators On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Biologics - Small Molecules On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Oral - Parenteral On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments. - Solid - Liquid Key Vendors - Abbvie - Biogen Idec - Janssen Pharmaceuticals - Merck & Company - Shire - UCB Other Prominent Vendors - Amgen - Akebia Therapeutics - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Galapagos - Genentech - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Salix Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vhn6mx/global
BIIB: 409.50 (+0.57), NVO: 58.35 (-0.53), MRK: 58.67 (-0.33), SLXP: 172.96 (+0.15), AMGN: 163.70 (-0.64), AKBA: 11.69 (+0.69), NVS: 103.71 (-2.41)
Earnings Loom For Handful Of Top Big Cap 20 Stocks
at Investor's Business Daily - Mon Jul 20, 5:50PM CDT
A handful of Big Cap 20 stocks are due to report quarterly earnings this week, but only one is expected to post accelerating profit growth. Starbucks (SBUX) will report fiscal Q3 earnings Thursday. Profit is seen rising 21% to 41 cents a share, which...
SBUX: 56.20 (-0.01), BIIB: 409.50 (+0.57), ILMN: 237.54 (-2.48), ABBV: 70.54 (-0.26), CELG: 136.24 (+1.01)
Biogen Idec Rises 1.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 409.50 (+0.57)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.06% Gain
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 409.50 (+0.57)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 317.00 (-0.75), AMBA: 118.18 (+0.46), NFLX: 112.51 (+1.96), BIIB: 409.50 (+0.57), GPRO: 62.04 (+1.24), AMZN: 488.00 (-0.10), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), FB: 98.39 (+0.48), GOOGL: 695.35 (+2.51), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01), MS: 40.08 (+0.04)
How to Navigate This Week's Earnings Minefield
at The Street - Mon Jul 20, 6:33AM CDT
Don't make a learning week a gambling week.
BIIB: 409.50 (+0.57), DAL: 44.65 (+0.56), SLB: 84.30 (+0.78), SBUX: 56.20 (-0.01), YHOO: 39.73 (+0.19), V: 72.02 (-0.68), JPM: 69.10 (-0.16), IBM: 163.07 (-10.15), CMG: 673.07 (-4.93), QCOM: 65.14 (+1.35), AAL: 40.90 (+0.35), ABBV: 70.54 (-0.26), GOOGL: 695.35 (+2.51), CAT: 82.22 (-0.03), MSFT: 47.28 (+0.36), AAPL: 130.75 (-1.32), BHI: 60.64 (+1.18), AMBA: 118.18 (+0.46), KO: 41.19 (-0.19), AMZN: 488.00 (-0.10), GPRO: 62.04 (+1.24), SWKS: 103.97 (+0.83), AXP: 78.95 (-0.35), HAL: 41.86 (+1.14), COP: 56.49 (-0.08), LLY: 85.57 (-2.30), NXPI: 92.40 (+2.39), BA: 145.00 (-1.72), MS: 40.08 (+0.04), NFLX: 112.51 (+1.96), GS: 211.50 (-0.89), QRVO: 77.45 (+0.75), MCD: 97.32 (-0.17), AVGO: 134.51 (-0.13), BABA: 82.54 (-0.13)
What to Watch in the Week Ahead: Apple Earnings, Housing Data
at The Street - Sun Jul 19, 11:15AM CDT
For the week of July 20, investors will see more than 100 S&P 500 companies report earnings -- including the one with the largest market cap in the world: Apple.
KO: 41.19 (-0.19), AMZN: 488.00 (-0.10), BIIB: 409.50 (+0.57), UTX: 102.71 (-7.77), VFC: 74.08 (+1.21), HAL: 41.86 (+1.14), BA: 145.00 (-1.72), MS: 40.08 (+0.04), SBUX: 56.20 (-0.01), YHOO: 39.73 (+0.19), T: 34.57 (-0.33), V: 72.02 (-0.68), IBM: 163.07 (-10.15), QCOM: 65.14 (+1.35), CMG: 673.07 (-4.93), GM: 30.39 (-0.11), MCD: 97.32 (-0.17), ABBV: 70.54 (-0.26), MSFT: 47.28 (+0.36), VZ: 46.97 (-1.13), AAPL: 130.75 (-1.32)
6 Big-Cap Drugmakers Reporting Earnings Next Week
at Investor's Business Daily - Sat Jul 18, 7:02AM CDT
Next week will bring a passel of earnings reports from large-cap drugmakers, as both biotech and pharma stocks are trading at new highs yet again. Novartis, Bristol-Myers Squibb, Eli Lilly, Valeant Pharmaceuticals, AbbVie and Biogen are all on tap in...
ZTS: 49.12 (+0.14), JNJ: 100.34 (-0.03), BIIB: 409.50 (+0.57), VRX: 240.59 (+0.71), ABBV: 70.54 (-0.26), LLY: 85.57 (-2.30), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41)
Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie
at The Street - Fri Jul 17, 5:45AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BIIB: 409.50 (+0.57), INSY: 42.03 (+0.06), XON: 56.77 (-1.18), LLY: 85.57 (-2.30), JUNO: 50.10 (-0.03)
Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 3:30PM CDT
Isis Pharmaceuticals (ISIS) earned a milestone payment of $2.15 million from Biogen for the advancement of ISIS-SMNRx in children with spinal muscular atrophy.
BIIB: 409.50 (+0.57), ISIS: 56.18 (+0.50), EBIO: 2.95 (-0.04), AMAG: 72.59 (-1.83)
Celgene Hits High As Street Applauds Receptos Buyout
at Investor's Business Daily - Wed Jul 15, 10:12AM CDT
Celgene (CELG) stock jumped 10% to a new high above 135 Wednesday morning as it got several price-target increases in the wake of its deal to buy Receptos (RCPT). Celgene agreed to pay $7.2 billion for Receptos and announced preliminary Q2 earnings...
BIIB: 409.50 (+0.57), GILD: 117.78 (-0.42), INCY: 113.87 (-1.90), RCPT: 228.98 (+0.26), LLY: 85.57 (-2.30), TEVA: 63.35 (-0.26), ARNA: 4.30 (-0.05), CELG: 136.24 (+1.01)
Stock Market News for July 15, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 9:10AM CDT
Gains in energy shares amid a rise in oil prices helped benchmarks end higher on Tuesday
JNJ: 100.34 (-0.03), BIIB: 409.50 (+0.57), JPM: 69.10 (-0.16), RIG: 13.35 (unch), GILD: 117.78 (-0.42), AMGN: 163.70 (-0.64), COP: 56.49 (-0.08), XOM: 81.66 (-0.10), WFC: 57.95 (-0.10), CVX: 93.90 (+0.96), SLB: 84.30 (+0.78), CELG: 136.24 (+1.01)
The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and Medicines Company - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 8:30AM CDT
The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and Medicines Company
BIIB: 409.50 (+0.57), VRX: 240.59 (+0.71), MDCO: 33.85 (+0.13), LLY: 85.57 (-2.30)
4 Health Care Stocks to Watch Out for this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 4:37PM CDT
Health care companies have been attracting a lot of attention lately.
BIIB: 409.50 (+0.57), VRX: 240.59 (+0.71), MDCO: 33.85 (+0.13), LLY: 85.57 (-2.30)
Biogen (BIIB) Stock Getting a Boost After Analyst Upgrade
at The Street - Tue Jul 14, 8:58AM CDT
Biogen (BIIB) stock is higher after the company was upgraded to 'buy' from 'neutral' at Bank of America/Merrill Lynch this morning.
BIIB: 409.50 (+0.57)
Big Week for Biogen
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 4:48PM CDT
Biogen 's investors are in store for a double dose of news this week. On Wednesday, the biotech is scheduled to present data for its Alzheimer's disease drug, aducanumab, and then on Friday we'll get second-quarter earnings from Biogen. Which will...
BIIB: 409.50 (+0.57)
Celgene Buys Receptos. Is Arena Pharmaceuticals Next?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 21, 3:27PM CDT
Arena Pharmaceuticals (NASDAQ: ARNA) jumped more than 6% last Wednesday. But it had nothing to do with the biotech's only approved drug, obesity treatment Belviq. It wasn't even anything Arena Pharmaceuticals did. Instead, it appears the bump...
BIIB: 409.50 (+0.57), RCPT: 228.98 (+0.26), ARNA: 4.30 (-0.05), NVS: 103.71 (-2.41), CELG: 136.24 (+1.01)
Will AmerisourceBergen (ABC) Disappoint Earnings in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 21, 11:50AM CDT
AmerisourceBergen carries a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00% and is scheduled to report third-quarter fiscal 2015 results on Jul 23, 2015.
BIIB: 409.50 (+0.57), ABC: 114.10 (-0.66), WBA: 95.66 (+0.01), MDCO: 33.85 (+0.13)
Why This Analyst Expects New Alzhemier’s Trials Could Produce the Most Important Drugs in History
ESTMZ - Tue Jul 21, 11:24AM CDT
Welcome to the July 21st edition of This Week on Estimize. We are pleased to be joined by Joe McCann, former biotech analyst and founder of Slingshot Insights, a company that works to provide professional caliber investment tools to sophisticated...
BIIB: 409.50 (+0.57), SPY: 211.75 (-0.84), GILD: 117.78 (-0.42), ZGNX: 20.72 (+0.34), UTHR: 175.17 (-2.34), RTRX: 34.47 (-0.68), LLY: 85.57 (-2.30), CELG: 136.24 (+1.01), XOMA: 4.39 (-0.13)
Global Inflammatory Bowel Disease Market 2015-2019 - Dominance of Market by Biologics
M2 - Tue Jul 21, 10:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vhn6mx/global) has announced the addition of the "Global Inflammatory Bowel Disease Market 2015-2019" report to their offering. This report covers the present scenario and the growth prospects of the Global Inflammatory Bowel Disease market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of inflammatory bowel disease. The market includes data from the sales of various drusg which are used for the treatment of Crohn's Disease and Ulcerative Colitis. The dominance of the market by biologics used to treat patients suffering from the disease is one of the emerging trends. Biologics are expected to become a preferred treatment option for the medical fraternity, patients, and the families of patients during the forecast period. This leads to a rise in the number of treatment-seeking patients, which increases the overall consumption of medicines. According to the report, the high prevalence of inflammatory bowel disease among the population resulting in a rise in the number of treatment-seeking patients has led to increased consumption of medications, thereby having a positive impact on the market share of the vendors. Further, the report states the high cost of drugs used to treat patients suffering from inflammatory bowel disease is one of the major challenges hindering the growth of the market. On the basis of the functioning of the drugs used for treatment, the Global Inflammatory Bowel Disease market is categorized into three segments. - 5-ASA - Antibiotics - Immunomodulators On the basis of the type of molecule used for treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Biologics - Small Molecules On the basis of route of administration adopted for the treatment, the Global Inflammatory Bowel Disease market is categorized into two segments. - Oral - Parenteral On the basis of the form of drug used to treat the disease, the Global Inflammatory Bowel Disease market is categorized into two segments. - Solid - Liquid Key Vendors - Abbvie - Biogen Idec - Janssen Pharmaceuticals - Merck & Company - Shire - UCB Other Prominent Vendors - Amgen - Akebia Therapeutics - Boehringer Ingelheim - Celltrion - ChemoCentryx - Ferring Pharmaceuticals - Galapagos - Genentech - Merck - Mitsubishi Tanabe - Novartis - Novo Nordisk - Pfizer - Salix Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/vhn6mx/global
BIIB: 409.50 (+0.57), NVO: 58.35 (-0.53), MRK: 58.67 (-0.33), SLXP: 172.96 (+0.15), AMGN: 163.70 (-0.64), AKBA: 11.69 (+0.69), NVS: 103.71 (-2.41)
Earnings Loom For Handful Of Top Big Cap 20 Stocks
at Investor's Business Daily - Mon Jul 20, 5:50PM CDT
A handful of Big Cap 20 stocks are due to report quarterly earnings this week, but only one is expected to post accelerating profit growth. Starbucks (SBUX) will report fiscal Q3 earnings Thursday. Profit is seen rising 21% to 41 cents a share, which...
SBUX: 56.20 (-0.01), BIIB: 409.50 (+0.57), ILMN: 237.54 (-2.48), ABBV: 70.54 (-0.26), CELG: 136.24 (+1.01)
Biogen Idec Rises 1.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 409.50 (+0.57)
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 1.06% Gain
Comtex SmarTrend(R) - Mon Jul 20, 3:51PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $403.01 to a high of $409.40. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $407.83 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
BIIB: 409.50 (+0.57)
Are Any New FANGs Baring Their Teeth?
at The Street - Mon Jul 20, 10:27AM CDT
The fearsome foursome have been reborn.
AGN: 317.00 (-0.75), AMBA: 118.18 (+0.46), NFLX: 112.51 (+1.96), BIIB: 409.50 (+0.57), GPRO: 62.04 (+1.24), AMZN: 488.00 (-0.10), VRX: 240.59 (+0.71), GILD: 117.78 (-0.42), FB: 98.39 (+0.48), GOOGL: 695.35 (+2.51), REGN: 560.00 (-1.17), CELG: 136.24 (+1.01), MS: 40.08 (+0.04)
How to Navigate This Week's Earnings Minefield
at The Street - Mon Jul 20, 6:33AM CDT
Don't make a learning week a gambling week.
BIIB: 409.50 (+0.57), DAL: 44.65 (+0.56), SLB: 84.30 (+0.78), SBUX: 56.20 (-0.01), YHOO: 39.73 (+0.19), V: 72.02 (-0.68), JPM: 69.10 (-0.16), IBM: 163.07 (-10.15), CMG: 673.07 (-4.93), QCOM: 65.14 (+1.35), AAL: 40.90 (+0.35), ABBV: 70.54 (-0.26), GOOGL: 695.35 (+2.51), CAT: 82.22 (-0.03), MSFT: 47.28 (+0.36), AAPL: 130.75 (-1.32), BHI: 60.64 (+1.18), AMBA: 118.18 (+0.46), KO: 41.19 (-0.19), AMZN: 488.00 (-0.10), GPRO: 62.04 (+1.24), SWKS: 103.97 (+0.83), AXP: 78.95 (-0.35), HAL: 41.86 (+1.14), COP: 56.49 (-0.08), LLY: 85.57 (-2.30), NXPI: 92.40 (+2.39), BA: 145.00 (-1.72), MS: 40.08 (+0.04), NFLX: 112.51 (+1.96), GS: 211.50 (-0.89), QRVO: 77.45 (+0.75), MCD: 97.32 (-0.17), AVGO: 134.51 (-0.13), BABA: 82.54 (-0.13)
What to Watch in the Week Ahead: Apple Earnings, Housing Data
at The Street - Sun Jul 19, 11:15AM CDT
For the week of July 20, investors will see more than 100 S&P 500 companies report earnings -- including the one with the largest market cap in the world: Apple.
KO: 41.19 (-0.19), AMZN: 488.00 (-0.10), BIIB: 409.50 (+0.57), UTX: 102.71 (-7.77), VFC: 74.08 (+1.21), HAL: 41.86 (+1.14), BA: 145.00 (-1.72), MS: 40.08 (+0.04), SBUX: 56.20 (-0.01), YHOO: 39.73 (+0.19), T: 34.57 (-0.33), V: 72.02 (-0.68), IBM: 163.07 (-10.15), QCOM: 65.14 (+1.35), CMG: 673.07 (-4.93), GM: 30.39 (-0.11), MCD: 97.32 (-0.17), ABBV: 70.54 (-0.26), MSFT: 47.28 (+0.36), VZ: 46.97 (-1.13), AAPL: 130.75 (-1.32)
6 Big-Cap Drugmakers Reporting Earnings Next Week
at Investor's Business Daily - Sat Jul 18, 7:02AM CDT
Next week will bring a passel of earnings reports from large-cap drugmakers, as both biotech and pharma stocks are trading at new highs yet again. Novartis, Bristol-Myers Squibb, Eli Lilly, Valeant Pharmaceuticals, AbbVie and Biogen are all on tap in...
ZTS: 49.12 (+0.14), JNJ: 100.34 (-0.03), BIIB: 409.50 (+0.57), VRX: 240.59 (+0.71), ABBV: 70.54 (-0.26), LLY: 85.57 (-2.30), BMY: 68.87 (-1.10), NVS: 103.71 (-2.41)
Biotech Stock Mailbag: Alzheimer's Conference Preview, Why Stock Prices Sometimes Lie
at The Street - Fri Jul 17, 5:45AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BIIB: 409.50 (+0.57), INSY: 42.03 (+0.06), XON: 56.77 (-1.18), LLY: 85.57 (-2.30), JUNO: 50.10 (-0.03)
Isis Pharmaceuticals Up on Milestone Payment from Biogen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 3:30PM CDT
Isis Pharmaceuticals (ISIS) earned a milestone payment of $2.15 million from Biogen for the advancement of ISIS-SMNRx in children with spinal muscular atrophy.
BIIB: 409.50 (+0.57), ISIS: 56.18 (+0.50), EBIO: 2.95 (-0.04), AMAG: 72.59 (-1.83)
Celgene Hits High As Street Applauds Receptos Buyout
at Investor's Business Daily - Wed Jul 15, 10:12AM CDT
Celgene (CELG) stock jumped 10% to a new high above 135 Wednesday morning as it got several price-target increases in the wake of its deal to buy Receptos (RCPT). Celgene agreed to pay $7.2 billion for Receptos and announced preliminary Q2 earnings...
BIIB: 409.50 (+0.57), GILD: 117.78 (-0.42), INCY: 113.87 (-1.90), RCPT: 228.98 (+0.26), LLY: 85.57 (-2.30), TEVA: 63.35 (-0.26), ARNA: 4.30 (-0.05), CELG: 136.24 (+1.01)
Stock Market News for July 15, 2015 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 9:10AM CDT
Gains in energy shares amid a rise in oil prices helped benchmarks end higher on Tuesday
JNJ: 100.34 (-0.03), BIIB: 409.50 (+0.57), JPM: 69.10 (-0.16), RIG: 13.35 (unch), GILD: 117.78 (-0.42), AMGN: 163.70 (-0.64), COP: 56.49 (-0.08), XOM: 81.66 (-0.10), WFC: 57.95 (-0.10), CVX: 93.90 (+0.96), SLB: 84.30 (+0.78), CELG: 136.24 (+1.01)
The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and Medicines Company - Press Releases
Zacks Equity Research - Zacks Investment Research - Wed Jul 15, 8:30AM CDT
The Zacks Analyst Blog Highlights: Eli Lilly, Valeant Pharmaceuticals International, Biogen and Medicines Company
BIIB: 409.50 (+0.57), VRX: 240.59 (+0.71), MDCO: 33.85 (+0.13), LLY: 85.57 (-2.30)
4 Health Care Stocks to Watch Out for this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Tue Jul 14, 4:37PM CDT
Health care companies have been attracting a lot of attention lately.
BIIB: 409.50 (+0.57), VRX: 240.59 (+0.71), MDCO: 33.85 (+0.13), LLY: 85.57 (-2.30)
Biogen (BIIB) Stock Getting a Boost After Analyst Upgrade
at The Street - Tue Jul 14, 8:58AM CDT
Biogen (BIIB) stock is higher after the company was upgraded to 'buy' from 'neutral' at Bank of America/Merrill Lynch this morning.
BIIB: 409.50 (+0.57)
